Tech Transfer eNews Blog

Kansas State U inks license agreement for antivirals targeting norovirus, coronavirus

By Jesse Schwartz
Published: February 26th, 2020

Kansas State University Research Foundation has signed a license agreement with Cocrystal Pharma Inc. to further develop proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections. 

The timely agreement, considering fears of a coronavirus pandemic, sent Cocrystal’s stock up more than four-fold since Monday’s announcement – from around $0.50 to $2.19 per share by Tuesday’s market close.

Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to preclinical and clinical development.

“We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, president of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.”

Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution, facilitating the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication.

Source: Cocrystal Pharma

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment